Biotech companies face the same dilemma as businesses in other industries: Innovation drops off dramatically with scale. European biotech Argenx has reached a market value of more than $40 billion, having so far escaped that innovation trap. How has it done this? The company shuns hierarchy and instead organizes into small teams, each dedicated to… →
The GTM Podcast is available on any major directory, including: Apple Podcasts Spotify YouTube Okta’s CRO Jon Addison joins GTMnow host Sophie to break down the full story behind Okta’s remarkable revenue turnaround, the launch of Okta for AI Agents, and the go-to-market playbook that’s carrying them from $3B toward a $5B ARR target. From nearly $850M… →
CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, almost one-third of the population met national genetic counseling criteria for an inherited cancer syndrome, highlighting a substantial gap in usual care identification. Integrating patient-facing FHH collection and assessment tools for primary care patients improves inherited cancer risk identification and highlights opportunities to further enhance both risk… →

SETTING: In France, participation rates in breast cancer screening have been decreasing, along with socio-territorial inequalities. To enhance women’s access to breast cancer screening, an interventional research project was implemented to assess the effectiveness, efficiency, and optimal modalities of a mobile mammography unit for women living remotely in Normandy. →

Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan-genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time-dependent inhibitor of CYP3A4. These results prompted further evaluation in… →

Vorasidenib was first approved in 2024 for the treatment of Grade 2 gliomas with isocitrate dehydrogenase 1 and 2 mutations and is now approved in over 40 countries, including Japan. During early development, vorasidenib pharmacokinetics (PK) was estimated in populations without Japanese participants. In 2019, this Phase 1 single ascending (two levels) dose study (NCT04145128)… →

CONCLUSION: In a large, real-world study designed to emulate a clinical trial, GLP-1 RAs were linked to increased psoriasis and decreased autoimmune blistering diseases compared with DPP-4is over up to 4 years’ follow-up. These results provide a dermatologic safety context to guide incretin therapy selection and highlight the importance of ongoing skin monitoring. →

Purpose: This study compares the accuracy of dental students in diagnosing different breathing sounds using traditional versus artificial intelligence-assisted precordial stethoscopes (AIPS). Methods: The study involved 45 3rd- and 4th-year dental students who completed a pre-test to assess their baseline knowledge of breathing sounds. After watching a learning video, participants were randomized into 3 groups:… →

CONCLUSION: SOX therapy as consolidation chemotherapy after CRT was safe and well tolerated as part of the TNT for lower rectal cancer. To our knowledge, this is the first study to report the use of SOX in TNT. Further trials are warranted to evaluate the efficacy of SOX as consolidation therapy after CRT in larger… →

The most important economic question in the AI era is not how many jobs will be replaced. It is whether AI is expanding human capacity: what we can imagine, do, and want. Youngjin Yoo argues that the demand frontier of human capacity — the outer limit of what people want, attempt, and are willing to… →